Network Expansion GTC’s new Houston facility expands its national testing network, enabling partnerships with regional hospitals, oncology practices, labs, and medical professionals to offer faster, cost-efficient NGS diagnostics. BD approach: target mid-sized community hospitals and ambulatory oncology centers in Texas and nearby states to onboard as cooperative partners, highlighting shared resources, reduced turnaround times, and improved patient access.

Co-Op Advantage The cooperative model lowers barriers for partners by sharing resources to reduce costs and improve quality. Sales angle: position as a low-risk, scalable pathway for labs and clinics lacking in-house NGS capacity to access comprehensive DNA and RNA profiling across solid tumors, hematologic neoplasms, and liquid biopsy.

Data Collaboration GTC’s history of data integration with Cota and presenting abstracts at major conferences signals opportunity to offer data analytics and real-world evidence collaborations with pharma, CROs, and academic centers.

Clinical Presence Active participation in ASH and SNO demonstrates credibility and thought leadership, creating sales momentum for partnerships with researchers and hospital networks seeking cutting-edge genomic diagnostics and collaborative studies.

Market Readiness With a growing focus on DNA and RNA profiling for hematologic tumors, solid tumors, and liquid biopsies, GTC is positioned to scale with large labs, pharma players, and academic centers needing expanded NGS capabilities and access to new markets.